Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biotheus Out-Licenses Global Rights for Bispecific Antibody and mAb to BioNTech

publication date: Jul 21, 2023

Zhuhai Biotheus formed a far-reaching research/license collaboration with BioNTech SE, the German COVID mRNA vaccine company that is now developing novel therapies for cancer and other diseases. Biotheus will grant BioNTech global options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer indications. The company will also grant BioNTech licenses to existing panels of VHH binders for multiple targets and options for new VHH binders against BioNTech chosen targets. In exchange, BioNTech will make an upfront payment and, following option exercise, Biotheus will be eligible for milestones and single digit royalties. More details....

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital